Endovascular repair of the thoracic aorta in the post-FDA approval era

Joshua D. Adams, John F. Angle, Alan H. Matsumoto, Benjamin B. Peeler, Bulent Arslan, Kenneth J. Cherry, John A. Kern, Michael D. Dake

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Objective: Endovascular repair of thoracic aortic disease is rapidly progressing as an alternative to open surgical therapy. In March of 2005, the Gore TAG thoracic endoprosthesis (W. L. Gore & Associates, Inc, Flagstaff, Ariz) received Food and Drug Administration (FDA) approval for the treatment of descending thoracic aortic aneurysms. Subsequently, off-label use of the technology expanded to include additional thoracic aortic diseases. The purpose of this study was to examine whether the outcomes with this device changed after the inclusion and exclusion criteria of FDA-controlled trials no longer governed patient selection. Methods: A retrospective analysis was performed on all patients who underwent endovascular repair of the thoracic aorta with the Gore TAG device at our institution between March 23, 2005, and September 8, 2006. Results: Fifty consecutive patients with a broad range of aortic pathologic conditions were included in the study. The results in this group compared with those of the phase II trial included the following: length of stay, 7.5 versus 7.6 days (P = .97); intensive care unit stay, 3.7 versus 2.6 days (P = .61); 30-day mortality, 2.0% versus 1.5% (P = .68); spinal cord injury, 2% versus 3% (P = .89); stroke, 4% versus 4% (P = .67); early endoleaks, 26% versus 4% (P < .01); and late endoleaks, 18% versus 7% (P = .08). At 1 year, overall survival was 92% compared with 82% in the phase II trial. Conclusions: In the post-FDA approval era, endovascular stent-graft therapy is frequently applied to patients with more challenging thoracic aortic anatomy and a wide range of pathologic conditions. Our results in this group are similar to outcomes reported for patients with descending thoracic aortic aneurysm exclusively.

Original languageEnglish (US)
Pages (from-to)117-123
Number of pages7
JournalJournal of Thoracic and Cardiovascular Surgery
Volume137
Issue number1
DOIs
StatePublished - Jan 1 2009
Externally publishedYes

Fingerprint

Drug Approval
United States Food and Drug Administration
Thoracic Aorta
Thoracic Diseases
Endoleak
Thoracic Aortic Aneurysm
Aortic Diseases
Thorax
Off-Label Use
Equipment and Supplies
Spinal Cord Injuries
Patient Selection
Stents
Intensive Care Units
Length of Stay
Anatomy
Therapeutics
Stroke
Technology
Transplants

ASJC Scopus subject areas

  • Surgery
  • Pulmonary and Respiratory Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Endovascular repair of the thoracic aorta in the post-FDA approval era. / Adams, Joshua D.; Angle, John F.; Matsumoto, Alan H.; Peeler, Benjamin B.; Arslan, Bulent; Cherry, Kenneth J.; Kern, John A.; Dake, Michael D.

In: Journal of Thoracic and Cardiovascular Surgery, Vol. 137, No. 1, 01.01.2009, p. 117-123.

Research output: Contribution to journalArticle

Adams, JD, Angle, JF, Matsumoto, AH, Peeler, BB, Arslan, B, Cherry, KJ, Kern, JA & Dake, MD 2009, 'Endovascular repair of the thoracic aorta in the post-FDA approval era', Journal of Thoracic and Cardiovascular Surgery, vol. 137, no. 1, pp. 117-123. https://doi.org/10.1016/j.jtcvs.2008.08.004
Adams, Joshua D. ; Angle, John F. ; Matsumoto, Alan H. ; Peeler, Benjamin B. ; Arslan, Bulent ; Cherry, Kenneth J. ; Kern, John A. ; Dake, Michael D. / Endovascular repair of the thoracic aorta in the post-FDA approval era. In: Journal of Thoracic and Cardiovascular Surgery. 2009 ; Vol. 137, No. 1. pp. 117-123.
@article{b015f99cebd147c2986679743716afd0,
title = "Endovascular repair of the thoracic aorta in the post-FDA approval era",
abstract = "Objective: Endovascular repair of thoracic aortic disease is rapidly progressing as an alternative to open surgical therapy. In March of 2005, the Gore TAG thoracic endoprosthesis (W. L. Gore & Associates, Inc, Flagstaff, Ariz) received Food and Drug Administration (FDA) approval for the treatment of descending thoracic aortic aneurysms. Subsequently, off-label use of the technology expanded to include additional thoracic aortic diseases. The purpose of this study was to examine whether the outcomes with this device changed after the inclusion and exclusion criteria of FDA-controlled trials no longer governed patient selection. Methods: A retrospective analysis was performed on all patients who underwent endovascular repair of the thoracic aorta with the Gore TAG device at our institution between March 23, 2005, and September 8, 2006. Results: Fifty consecutive patients with a broad range of aortic pathologic conditions were included in the study. The results in this group compared with those of the phase II trial included the following: length of stay, 7.5 versus 7.6 days (P = .97); intensive care unit stay, 3.7 versus 2.6 days (P = .61); 30-day mortality, 2.0{\%} versus 1.5{\%} (P = .68); spinal cord injury, 2{\%} versus 3{\%} (P = .89); stroke, 4{\%} versus 4{\%} (P = .67); early endoleaks, 26{\%} versus 4{\%} (P < .01); and late endoleaks, 18{\%} versus 7{\%} (P = .08). At 1 year, overall survival was 92{\%} compared with 82{\%} in the phase II trial. Conclusions: In the post-FDA approval era, endovascular stent-graft therapy is frequently applied to patients with more challenging thoracic aortic anatomy and a wide range of pathologic conditions. Our results in this group are similar to outcomes reported for patients with descending thoracic aortic aneurysm exclusively.",
author = "Adams, {Joshua D.} and Angle, {John F.} and Matsumoto, {Alan H.} and Peeler, {Benjamin B.} and Bulent Arslan and Cherry, {Kenneth J.} and Kern, {John A.} and Dake, {Michael D.}",
year = "2009",
month = "1",
day = "1",
doi = "10.1016/j.jtcvs.2008.08.004",
language = "English (US)",
volume = "137",
pages = "117--123",
journal = "Journal of Thoracic and Cardiovascular Surgery",
issn = "0022-5223",
publisher = "Mosby Inc.",
number = "1",

}

TY - JOUR

T1 - Endovascular repair of the thoracic aorta in the post-FDA approval era

AU - Adams, Joshua D.

AU - Angle, John F.

AU - Matsumoto, Alan H.

AU - Peeler, Benjamin B.

AU - Arslan, Bulent

AU - Cherry, Kenneth J.

AU - Kern, John A.

AU - Dake, Michael D.

PY - 2009/1/1

Y1 - 2009/1/1

N2 - Objective: Endovascular repair of thoracic aortic disease is rapidly progressing as an alternative to open surgical therapy. In March of 2005, the Gore TAG thoracic endoprosthesis (W. L. Gore & Associates, Inc, Flagstaff, Ariz) received Food and Drug Administration (FDA) approval for the treatment of descending thoracic aortic aneurysms. Subsequently, off-label use of the technology expanded to include additional thoracic aortic diseases. The purpose of this study was to examine whether the outcomes with this device changed after the inclusion and exclusion criteria of FDA-controlled trials no longer governed patient selection. Methods: A retrospective analysis was performed on all patients who underwent endovascular repair of the thoracic aorta with the Gore TAG device at our institution between March 23, 2005, and September 8, 2006. Results: Fifty consecutive patients with a broad range of aortic pathologic conditions were included in the study. The results in this group compared with those of the phase II trial included the following: length of stay, 7.5 versus 7.6 days (P = .97); intensive care unit stay, 3.7 versus 2.6 days (P = .61); 30-day mortality, 2.0% versus 1.5% (P = .68); spinal cord injury, 2% versus 3% (P = .89); stroke, 4% versus 4% (P = .67); early endoleaks, 26% versus 4% (P < .01); and late endoleaks, 18% versus 7% (P = .08). At 1 year, overall survival was 92% compared with 82% in the phase II trial. Conclusions: In the post-FDA approval era, endovascular stent-graft therapy is frequently applied to patients with more challenging thoracic aortic anatomy and a wide range of pathologic conditions. Our results in this group are similar to outcomes reported for patients with descending thoracic aortic aneurysm exclusively.

AB - Objective: Endovascular repair of thoracic aortic disease is rapidly progressing as an alternative to open surgical therapy. In March of 2005, the Gore TAG thoracic endoprosthesis (W. L. Gore & Associates, Inc, Flagstaff, Ariz) received Food and Drug Administration (FDA) approval for the treatment of descending thoracic aortic aneurysms. Subsequently, off-label use of the technology expanded to include additional thoracic aortic diseases. The purpose of this study was to examine whether the outcomes with this device changed after the inclusion and exclusion criteria of FDA-controlled trials no longer governed patient selection. Methods: A retrospective analysis was performed on all patients who underwent endovascular repair of the thoracic aorta with the Gore TAG device at our institution between March 23, 2005, and September 8, 2006. Results: Fifty consecutive patients with a broad range of aortic pathologic conditions were included in the study. The results in this group compared with those of the phase II trial included the following: length of stay, 7.5 versus 7.6 days (P = .97); intensive care unit stay, 3.7 versus 2.6 days (P = .61); 30-day mortality, 2.0% versus 1.5% (P = .68); spinal cord injury, 2% versus 3% (P = .89); stroke, 4% versus 4% (P = .67); early endoleaks, 26% versus 4% (P < .01); and late endoleaks, 18% versus 7% (P = .08). At 1 year, overall survival was 92% compared with 82% in the phase II trial. Conclusions: In the post-FDA approval era, endovascular stent-graft therapy is frequently applied to patients with more challenging thoracic aortic anatomy and a wide range of pathologic conditions. Our results in this group are similar to outcomes reported for patients with descending thoracic aortic aneurysm exclusively.

UR - http://www.scopus.com/inward/record.url?scp=58249087016&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58249087016&partnerID=8YFLogxK

U2 - 10.1016/j.jtcvs.2008.08.004

DO - 10.1016/j.jtcvs.2008.08.004

M3 - Article

C2 - 19154913

AN - SCOPUS:58249087016

VL - 137

SP - 117

EP - 123

JO - Journal of Thoracic and Cardiovascular Surgery

JF - Journal of Thoracic and Cardiovascular Surgery

SN - 0022-5223

IS - 1

ER -